CompanyREPLNasdaqWoburn, MA

Replimune, Inc.

Replimune develops oncolytic immunotherapies based on a modified HSV-1 platform designed to induce immunogenic cell death and systemic anti-tumor immune responses.

Stories only

SEC EDGAR ClinicalTrials.gov replimune.com

8-KSep 16Latest SEC filing, period to Sep 15

Aug 14Latest story

August 2026

Replimune's TUDRIQEV wins FDA accelerated approval, launch set within 60 days

Aug 14Quarterly updateReplimune, Inc.

Replimune's $150 million offering formalized in prospectus supplement filed with SEC

Aug 10FinancingReplimune, Inc.

FDA grants accelerated approval to Replimune's TUDRIQEV plus nivolumab for melanoma

Aug 6Regulatory decisionnivolumab Replimune, Inc.

July 2026

FDA advisory committee backs RP1 efficacy data in advanced melanoma, 10-3

Jul 30Regulatory milestoneReplimune, Inc.

June 2026

Replimune's RP1 BLA resubmission accepted by FDA; adcomm expected late July

Jun 29Quarterly updateReplimune, Inc.